FDA Panel votes for safety, effectiveness for the Glaukos iStent.
December 11, 2010
FDA Ophthalmic Device Panel Meeting, July 30, 2010 | www.fdalive.com
On July 30, 2010, the Ophthalmic Devices Panel reviewed data for the iStent, a trabecular micro-bypass shunt from Glaukos Corporation. The Panel voted 7 – 1 that there is a reasonable assurance of safety, 6 – 2 that there is a reasonable assurance of effectiveness, and 7 – 1 that there is a favorable risk/benefit ratio. At the end of the day, it was the perspective of two glaucoma subspecialists sitting on the Panel, Eve Higginbotham and Anne Coleman, that carried the greatest weight.
July 2010...B+L Voluntarily Recalls ReNu Multi-Purpose Solution
July 10, 2010
B+L Voluntarily Recalls Certain ReNu Multi-Purpose Solution and ReNu MultiPlus Multi-Purpose Solution in Europe and Middle East | www.visionmonday.com
No this is not 2007! A new problem has occurred in the manufacturing of Baucsh & Lomb's current signature contact lens disinfecting product, ReNu. Bausch has just released BioTrue, the next best product in Contact Lens care about 2 weeks ago.
Abbott back in contact lens solution game
June 12, 2010
Abbott back in contact lens solution game | www.chicagobreakingbusiness.com
There are new regulations and new contact lens solutions being announced almost weekly. Both Abbott and Bausch & Lomb have released new information on contact lens solutions. The industry leader Alcon's OptiFree with almost 33% of the retail US market should announce a new solution soon.
New Contact Lens Products in the Pipeline From J&J (JNJ)
June 4, 2010
UPDATE 3-J&J sees fast-growing device market | www.reuters.com
At the 2nd qtr reports for Johnson & Johnson Vision (JNJ) products a new announcement for allergy sufferers can lead to a new vehicle for introduction of medications in the eye, and the whole body.
Femtosecond Lasers Come to Cataract Surgery
March 26, 2010
Femtosecond laser cataract surgery | bmctoday.net
Cataract surgeons are impelled by their inward drive towards perfection to love the possibilities that femtosecond phaco creates. This technology changes everything. The pioneers of phaco, and the surgical techniques they developed that are still in use today, are coming to appear as the devices of medieval artisans relative to the streamlined accuracy of a nascent industrial era.
Digital 3D HD Imaging Gains Traction in the Ophthalmic OR
February 21, 2010
TrueVision Systems Releases First Ever 3D Visualization and Guidance Platform for Microsurgery | www.microscopy-news.com
There are tremendous applications for 3D HD surgery in ophthalmology, from education to archiving to enhancing surgical outcomes. As this technology moves forward through incision marking and toric intraocular lens placement with the Ophthalmic Tool Set, the capabilities of 3D surgery will surpass what we have in the standard microscope.
Alcon Expanding Its Drug Offerings and Pipeline with 3 Medications
January 20, 2010
Alcon to purchase rights for two eye care products from Sirion Therapeutics | www.pharmabiz.com
The rights for the the new anti inflammatory medication Durezol is Hot. The rights for Zirgan is a much smaller market, but there is limited competition in that field.The New Dry Eye Syndrome medication for Ocular Surface Disease is the first potential since the blockbuster medication Restasis. This is undergoing clinical clinical testing now. There are one or two other Dry Eye Syndrome medications coming down the pipeline.
Alcon would make a nice prize for Novartis
January 4, 2010
Top News Bloomberg Novartis May Sell Bonds in 2010 for $28.2 Billion Alcon Deal | www.businessweek.com
It looks like Novartis AG is gearing up to purchase the rest of Alcon, Inc.
What happens to the "Lifetime" guarantee?
December 21, 2009
TLC Vision, Tiger Woods Sponsor, Files for Bankruptcy | www.bloomberg.com
TLC Vision Corp (TLC), The Laser Center, marketed their Lifetime touch up at no additional charge. What happens now that they have declared chapter 11 bankruptcy as of 12/21/2009?
December 17, 2009
Optonol: Reaping $180m from a device the size of a grain of rice | www.haaretz.com
Alcon, the U.S. eye care pharmaceuticals and devices giant, announced this week that it will acquire Optonol, an Israeli company that manufactures the Ex-PRESS glaucoma mini-shunt. This innovative shunt has demonstrated good results in the reduction of intraocular pressure, with investigators reporting about 95% success at 3 years (http://community.modernmedicine.com/_Growing-Glaucoma-ProceduresECP-and-the-Ex-PRESS-Shunt/blog/439235/33379.html).
February 7, 2012
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
Medtech M&A activity accelerates in 2011
November 30, 2011